{"id":56243,"date":"2023-04-26T15:06:38","date_gmt":"2023-04-26T13:06:38","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\/"},"modified":"2023-04-26T15:06:38","modified_gmt":"2023-04-26T13:06:38","slug":"artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\/","title":{"rendered":"Artiva Biotherapeutics Announces Presentation of Data from First-in-Human Phase 1\/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting"},"content":{"rendered":"
\n

SAN DIEGO–(BUSINESS WIRE)–#ASCO23<\/a>—Artiva Biotherapeutics, Inc.<\/a>, a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today that a poster describing initial data from the Phase 1\/2 trial of AB-101 will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago. AB-101 is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell being investigated in combination with rituximab for the treatment of relapsed\/refractory B-cell non-Hodgkin lymphoma.<\/p>\n

<\/a><\/p>\n

\nDetails of the presentation are as follows:<\/p>\n

\nTitle: <\/b>AB-101, an allogeneic, non\u2013genetically modified, natural killer (NK) cell therapy, evaluated as monotherapy or in combination with rituximab in R\/R non-Hodgkin lymphoma.
\n
Abstract: <\/b>7529
\n
Session: <\/b>Hematologic Malignancies\u2014Lymphoma and Chronic Lymphocytic Leukemia
\n
Session Day and Time:<\/b> Monday, June 5, 8 am to 11 am CT
\n
Presenter: <\/b>Thorsten Graef, M.D., Chief Medical Officer, Artiva Biotherapeutics<\/p>\n

\nAbout AB-101<\/b><\/p>\n

\nAB-101 is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers in the out-patient setting. Artiva selects cord blood units with the high affinity variant of the receptor CD16 and a KIR-B haplotype for enhanced product activity. Using the Company\u2019s AlloNKTM<\/sup> platform, Artiva can generate thousands of doses of pure, cryopreserved, infusion-ready NK cells from a single umbilical cord blood unit while retaining the high and consistent expression of CD16 and other tumor-engaging receptors, without the need for engineering. We believe this makes AB-101 an optimal adjunct therapy to targeted, ADCC-mechanistic biologics.<\/p>\n

\nArtiva is conducting a Phase 1\/2 multicenter clinical trial (ClinicalTrials.gov Identifier: NCT04673617) to assess the safety and clinical activity of AB-101 alone and in combination with the anti-CD20 monoclonal antibody, rituximab, in patients with relapsed or refractory B-cell-non-Hodgkin lymphoma (NHL) who have progressed beyond two or more prior lines of therapy including CAR-T therapy. This study is progressing at multiple clinical sites across the U.S., and AB-101 is administered weekly in the out-patient setting over one-month cycles and with up to four cycles to assess therapeutic efficacy and durability. Artiva is also collaborating with Affimed N.V. in developing a combination therapy, comprised of AB-101 and the Innate Cell Engager AFM13, for the treatment of patients with relapsed\/refractory CD30-positive lymphomas.<\/p>\n

\nAbout Artiva Biotherapeutics<\/b><\/p>\n

\nArtiva\u2019s mission is to deliver highly effective, off-the-shelf, allogeneic NK cell-based therapies utilizing our Manufacturing-First approach, that are safe and accessible to cancer patients. Artiva\u2019s pipeline includes AB-101, an ADCC enhancer NK-cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers. Artiva is currently advancing a Phase 1\/2 clinical trial of AB-101 in combination with rituximab for the treatment of relapsed or refractory B-cell lymphomas and is also combining AB-101 with Affimed N.V.\u2019s Innate Cell Engager AFM13 for the treatment of patients with relapsed\/refractory CD30-positive lymphomas. Artiva\u2019s pipeline also includes AB-201, an anti-HER2 CAR-NK cell therapy candidate for the treatment of HER2-overexpressing tumors, such as breast, gastric, and bladder cancers, and for which an IND has been allowed by FDA, and a pipeline of CAR-NK candidates targeting both solid and hematopoietic cancers. Artiva has entered into therapeutic NK cell collaborations with Merck & Co., Inc. and with Affimed N.V. Artiva\u2019s AlloNK\u2122 platform<\/a> incorporates cell expansion, activation, and engineering technology developed by Artiva\u2019s strategic partner, GC Cell Corporation, a member of the GC family of companies, a leading healthcare company in Korea. Artiva is headquartered in San Diego. For more information, visit www.artivabio.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:<\/b> Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com<\/a>, +1.858.344.8091<\/p>\n

\nInvestors:<\/b> Nicholas Veomett, Ph.D., Artiva Biotherapeutics, ir@artivabio.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO–(BUSINESS WIRE)–#ASCO23—Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today that a poster describing initial data from the Phase 1\/2 trial of AB-101 will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56243","6":"format-standard","7":"category-industry"},"yoast_head":"\nArtiva Biotherapeutics Announces Presentation of Data from First-in-Human Phase 1\/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Artiva Biotherapeutics Announces Presentation of Data from First-in-Human Phase 1\/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO–(BUSINESS WIRE)–#ASCO23—Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today that a poster describing initial data from the Phase 1\/2 trial of AB-101 will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-26T13:06:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230426005062\/en\/801115\/21\/Artiva_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Artiva Biotherapeutics Announces Presentation of Data from First-in-Human Phase 1\\\/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting\",\"datePublished\":\"2023-04-26T13:06:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\\\/\"},\"wordCount\":630,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230426005062\\\/en\\\/801115\\\/21\\\/Artiva_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\\\/\",\"name\":\"Artiva Biotherapeutics Announces Presentation of Data from First-in-Human Phase 1\\\/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230426005062\\\/en\\\/801115\\\/21\\\/Artiva_Logo.jpg\",\"datePublished\":\"2023-04-26T13:06:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230426005062\\\/en\\\/801115\\\/21\\\/Artiva_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230426005062\\\/en\\\/801115\\\/21\\\/Artiva_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Artiva Biotherapeutics Announces Presentation of Data from First-in-Human Phase 1\\\/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Artiva Biotherapeutics Announces Presentation of Data from First-in-Human Phase 1\/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Artiva Biotherapeutics Announces Presentation of Data from First-in-Human Phase 1\/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting - Pharma Trend","og_description":"SAN DIEGO–(BUSINESS WIRE)–#ASCO23—Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today that a poster describing initial data from the Phase 1\/2 trial of AB-101 will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-26T13:06:38+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230426005062\/en\/801115\/21\/Artiva_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Artiva Biotherapeutics Announces Presentation of Data from First-in-Human Phase 1\/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting","datePublished":"2023-04-26T13:06:38+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\/"},"wordCount":630,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230426005062\/en\/801115\/21\/Artiva_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\/","name":"Artiva Biotherapeutics Announces Presentation of Data from First-in-Human Phase 1\/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230426005062\/en\/801115\/21\/Artiva_Logo.jpg","datePublished":"2023-04-26T13:06:38+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230426005062\/en\/801115\/21\/Artiva_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230426005062\/en\/801115\/21\/Artiva_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/artiva-biotherapeutics-announces-presentation-of-data-from-first-in-human-phase-1-2-clinical-trial-of-ab-101-at-the-2023-asco-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Artiva Biotherapeutics Announces Presentation of Data from First-in-Human Phase 1\/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56243","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56243"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56243\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56243"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56243"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56243"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}